| Literature DB >> 30783805 |
Arthur Hosmann1,2, Felix Hinker1, Christian Dorfer1,2, Irene Slavc2,3, Christine Haberler2,4, Karin Dieckmann2,5, Engelbert Knosp1,2, Thomas Czech6,7.
Abstract
BACKGROUND: Choroid plexus tumors are rare entities. Resection is the mainstay of treatment in grade I and grade II tumors and adjuvant treatment is usually reserved for the less frequent choroid plexus carcinoma (CPC). Outcome is not only related to their histological grade but also dependent on their size, location, and presence of often multifactorial disturbances of cerebrospinal fluid (CSF) circulation.Entities:
Keywords: Atypical choroid plexus papilloma; Choroid plexus carcinoma; Choroid plexus papilloma; Choroid plexus tumor; Gross-total resection; Infiltration
Year: 2019 PMID: 30783805 PMCID: PMC6431303 DOI: 10.1007/s00701-019-03832-5
Source DB: PubMed Journal: Acta Neurochir (Wien) ISSN: 0001-6268 Impact factor: 2.216
Demographics, clinics, resection details, and outcome of all included patients. CPA, cerebellopontine angle; CR, complete remission; DOD, dead of disease; f, female; GTR, gross-total resection; lat., lateral; LOF, lost of follow-up; m, male; SD, stable disease; SDP, subduro-peritoneal; STR, subtotal resection; VA, ventriculo-atrial; VP, ventriculo-peritoneal
| Patient no. | Age (years) | Sex | WHO | Localization | Metastasis | Resection | Infiltration zones | Adjuvant treatment | Relapse | No. of local tumor resections | Permanent CSF diversion | Follow-up (years) | Tumor state | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Children | 1 | 0.8 | w | I | lat. ventricle | No | GTR | No | No | No | 1 | No | 7.8 | CR |
| 2 | 0.8 | m | I | 3rd ventricle | No | GTR | No | No | No | 1 | No | 21.5 | CR | |
| 3 | 0.8 | m | I | lat. ventricle | No | GTR | No | No | No | 1 | No | 19.2 | CR | |
| 4 | 1.5 | w | I | lat. ventricle | No | GTR | No | No | No | 1 | No | 9.8 | CR | |
| 5 | 3.1 | m | I | 3rd ventricle | No | GTR | No | No | No | 1 | No | 22.7 | CR | |
| 6 | 4.1 | w | I | lat. ventricle | No | GTR | No | No | No | 1 | No | 2.5 | CR | |
| 7 | 9.1 | w | I | 4th ventricle | No | GTR | Yes | No | No | 1 | No | 13.6 | CR | |
| 8 | 10.2 | w | I | lat. ventricle | No | GTR | No | No | No | 1 | No | 22.6 | CR | |
| 9 | 0.2 | w | II | lat. ventricle | No | GTR | No | No | Yes | 2 | SDP | 6.7 | SD | |
| 10 | 0.3 | w | II | lat. ventricle | No | GTR | Yes | No | No | 1 | No | 15.2 | CR | |
| 11 | 0.6 | m | II | lat. ventricle | No | GTR | No | No | No | 1 | No | 0.3 | CR | |
| 12 | 1 | w | II | 3rd ventricle | No | GTR | No | No | No | 1 | No | 0.3 | CR | |
| 13 | 1.2 | m | II | 3rd ventricle | No | GTR | No | No | No | 1 | SDP | 3.1 | CR | |
| 14 | 0.5 | m | III | lat. ventricle | No | GTR | Yes | Chemo | No | 1 | VP | 1.3 | SD | |
| 15 | 2.8 | m | III | lat. ventricle | At diagnosis | GTR | Yes | Chemo-radiation | No | 1 | VP, SDP | 8.6 | SD | |
| 16 | 5.3 | m | III | lat. ventricle | At diagnosis | STR | Yes | Chemo-radiation | Yes | 2 | VP | 8.2 | DOD | |
| 17 | 6.5 | w | III | lat. ventricle | No | GTR | Yes | Chemo | Yes | 1 | No | 23.3 | SD | |
| Adults | 18 | 22.7 | w | I | CPA | No | GTR | No | No | No | 1 | No | 16.8 | CR |
| 19 | 27.2 | w | I | 4th ventricle | No | GTR | No | No | No | 1 | No | 1.5 | CR | |
| 20 | 29 | w | I | 4th ventricle | No | GTR | No | No | No | 1 | No | 8.7 | CR | |
| 21 | 31.3 | w | I | 4th ventricle | No | GTR | No | No | No | 1 | VA | 17.4 | CR | |
| 22 | 40.2 | w | I | CPA | No | GTR | No | No | No | 1 | No | 0.1 | LOF | |
| 23 | 46.6 | w | I | 4th ventricle | No | GTR | No | No | No | 1 | No | 0.1 | CR | |
| 24 | 48.5 | w | I | 4th ventricle | No | GTR | No | No | No | 1 | No | 1.9 | CR | |
| 25 | 52 | w | I | 4th ventricle | No | GTR | No | No | No | 1 | VP | 2.1 | CR | |
| 26 | 52.7 | m | I | 4th ventricle | No | GTR | Yes | No | Yes | 1 | No | 20.6 | SD | |
| 27 | 53.2 | m | I | CPA | No | GTR | No | No | No | 1 | No | 0.0 | DOD | |
| 28 | 54.9 | w | I | 4th ventricle | No | GTR | No | No | No | 1 | No | 0.0 | LOF | |
| 29 | 58.9 | w | I | 4th ventricle | No | GTR | No | No | No | 1 | No | 18.5 | CR | |
| 30 | 60.9 | w | I | CPA | No | GTR | No | No | No | 1 | No | 0.3 | LOF | |
| 31 | 33.7 | w | II | 4th ventricle | Follow-up | STR | Yes | No | Yes | 2 | No | 9.5 | DOD | |
| 32 | 34.7 | m | II | 4th ventricle | No | GTR | Yes | No | Yes | 3 | VP | 15.8 | SD | |
| 33 | 46.8 | w | II | 4th ventricle | No | STR | Yes | Chemo | Yes | 2 | No | 9.9 | SD | |
| 34 | 54 | m | II | 4th ventricle | No | GTR | Yes | Radiation | Yes | 1 | No | 4.1 | SD | |
| 35 | 57.8 | m | II | 4th ventricle | No | GTR | Yes | Radiation | No | 1 | No | 0.2 | LOF | |
| 36 | 70.9 | m | II | 4th ventricle | No | GTR | No | No | Yes | 3 | VA | 9.0 | DOD |
Clinical presentation
| Children | Adults | |
|---|---|---|
| Increased ICP | 76.5% | 15.8%* |
| Increased head circumference | 41.2% | N/A |
| Headache | 23.5% | 68.4%* |
| Gait disturbance | 5.6% | 52.6%* |
| Vertigo | 7.1% | 36.8%* |
| Diplopia | 11.8% | 31.6% |
| Behavior | 35.3% | 5.3%* |
| Paresis | 17.6% | 10.5% |
| Incidential finding | 5.9% | 21.1% |
*Significant differences between age groups (p < 0.05)
Tumor localization and surgical approach
| Lat. ventricle | 3rd ventricle | 4th ventricle | CPA | |
|---|---|---|---|---|
| Suboccipital | – | – | 16 | 1 |
| Transcortical | 8 | 1 | – | – |
| Transcallosal | 4 | 2 | – | – |
| Supracerebellar | – | 1 | – | – |
| Retromastoidal | – | – | – | 3 |
| Total | 12 | 4 | 16 | 4 |
Fig. 2Illustrative case no. 9. A 2-month-old girl presented with increased head circumference (> 97th percentile) and a contrast-enhanced intraventricular lesion at the Foramen of Monro (a). Using a transcallosal approach the tumor was totally resected (b) and histopathology diagnosed an atypical choroid plexus papilloma. Pre-operative hydrocephalus resolved, but a subduro-peritoneal shunt was necessary due to postoperative persistent subdural hygroma (c). Follow-up MRI scans revealed tumor recurrence 7 months after primary surgery (d), which was resected via a transcallosal approach. Long-term follow-up (6.7 years) showed complete remission and excellent neurological outcome
Fig. 1Kaplan–Meier plot displaying progression-free survival (a, b) and overall survival (c, d) in relation to histological tumor grade and extent of resection. aCPP, atypical choroid plexus papilloma; CPC, choroid plexus carcinoma; CPP, choroid plexus papilloma; GTR, gross-total resection; STR, subtotal resection
Fig. 3Percentage of histological grading in children and adults
Fig. 4Kaplan–Meier plot displaying progression-free survival (a) and overall survival (b) for children and adults